Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) Target Price at $57.20

Shares of Silence Therapeutics plc (NASDAQ:SLN) have earned a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $57.20.

A number of analysts have commented on the stock. Jefferies Financial Group assumed coverage on shares of Silence Therapeutics in a report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and issued a $49.00 price objective on shares of Silence Therapeutics in a report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, November 15th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Finally, Chardan Capital reiterated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Thursday, November 14th.

Silence Therapeutics Stock Up 2.9 %

SLN opened at $7.21 on Tuesday. Silence Therapeutics has a twelve month low of $5.81 and a twelve month high of $27.72. The company has a 50-day moving average price of $16.68 and a 200 day moving average price of $18.52. The company has a market cap of $215.80 million, a PE ratio of -4.59 and a beta of 1.30.

Hedge Funds Weigh In On Silence Therapeutics

Institutional investors have recently modified their holdings of the business. Values First Advisors Inc. acquired a new position in shares of Silence Therapeutics in the third quarter worth $56,000. Quarry LP acquired a new position in shares of Silence Therapeutics during the second quarter worth $114,000. SG Americas Securities LLC grew its stake in shares of Silence Therapeutics by 10.5% during the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after purchasing an additional 667 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of Silence Therapeutics during the third quarter worth $207,000. Finally, Custom Index Systems LLC acquired a new position in shares of Silence Therapeutics during the second quarter worth $282,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.